CytomX Therapeutics Inc CTMX

Healthcare Biotechnology

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

NDAQ:CTMX - Post by User

CytomX Therapeutics Inc

<< Previous

Bullboard Posts

Post by whytestockson May 09, 2024 5:30pm

63 Views

Post# 36032270

Analysts' Varied Perspectives On CytomX's CX-904 Cancer Stud

Just In: $CTMX Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer | BenzingaWednesday, CytomX Therapeutics Inc (NASDAQ:CTMX) released initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, d...CTMX - Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer | Benzinga

<< Previous

Bullboard Posts

Nvidia reports record revenue in Q3